1
|
Mohammadnejad A, Soerensen M, Baumbach J, Mengel‐From J, Li W, Lund J, Li S, Christiansen L, Christensen K, Hjelmborg JVB, Tan Q. Novel DNA methylation marker discovery by assumption-free genome-wide association analysis of cognitive function in twins. Aging Cell 2021; 20:e13293. [PMID: 33528912 PMCID: PMC7884045 DOI: 10.1111/acel.13293] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2020] [Revised: 11/23/2020] [Accepted: 12/01/2020] [Indexed: 01/23/2023] Open
Abstract
Privileged by rapid increase in available epigenomic data, epigenome-wide association studies (EWAS) are to make a profound contribution to understand the molecular mechanism of DNA methylation in cognitive aging. Current statistical methods used in EWAS are dominated by models based on multiple assumptions, for example, linear relationship between molecular profiles and phenotype, normal distribution for the methylation data and phenotype. In this study, we applied an assumption-free method, the generalized correlation coefficient (GCC), and compare it to linear models, namely the linear mixed model and kinship model. We use DNA methylation associated with a cognitive score in 400 and 206 twins as discovery and replication samples respectively. DNA methylation associated with cognitive function using GCC, linear mixed model, and kinship model, identified 65 CpGs (p < 1e-04) from discovery sample displaying both nonlinear and linear correlations. Replication analysis successfully replicated 9 of these top CpGs. When combining results of GCC and linear models to cover diverse patterns of relationships, we identified genes like KLHDC4, PAPSS2, and MRPS18B as well as pathways including focal adhesion, axon guidance, and some neurological signaling. Genomic region-based analysis found 15 methylated regions harboring 11 genes, with three verified in gene expression analysis, also the 11 genes were related to top functional clusters including neurohypophyseal hormone and maternal aggressive behaviors. The GCC approach detects valuable methylation sites missed by traditional linear models. A combination of methylation markers from GCC and linear models enriched biological pathways sensible in neurological function that could implicate cognitive performance and cognitive aging.
Collapse
Affiliation(s)
- Afsaneh Mohammadnejad
- Unit of Epidemiology, Biostatistics and BiodemographyDepartment of Public HealthUniversity of Southern DenmarkOdenseDenmark
| | - Mette Soerensen
- Unit of Epidemiology, Biostatistics and BiodemographyDepartment of Public HealthUniversity of Southern DenmarkOdenseDenmark
- Unit of Human GeneticsDepartment of Clinical ResearchUniversity of Southern DenmarkOdenseDenmark
- Department of Clinical Biochemistry and PharmacologyOdense University HospitalOdenseDenmark
| | - Jan Baumbach
- Computational BiomedicineDepartment of Mathematics and Computer ScienceUniversity of Southern DenmarkOdenseDenmark
- Chair of Experimental BioinformaticsTUM School of Life SciencesTechnical University of MunichMunichGermany
| | - Jonas Mengel‐From
- Unit of Epidemiology, Biostatistics and BiodemographyDepartment of Public HealthUniversity of Southern DenmarkOdenseDenmark
- Unit of Human GeneticsDepartment of Clinical ResearchUniversity of Southern DenmarkOdenseDenmark
| | - Weilong Li
- Unit of Epidemiology, Biostatistics and BiodemographyDepartment of Public HealthUniversity of Southern DenmarkOdenseDenmark
- Population Research UnitFaculty of Social SciencesUniversity of HelsinkiHelsinkiFinland
| | - Jesper Lund
- Unit of Epidemiology, Biostatistics and BiodemographyDepartment of Public HealthUniversity of Southern DenmarkOdenseDenmark
- Digital Health & Machine Learning Research GroupHasso Plattner Institute for Digital EngineeringPotsdamGermany
| | - Shuxia Li
- Unit of Epidemiology, Biostatistics and BiodemographyDepartment of Public HealthUniversity of Southern DenmarkOdenseDenmark
| | - Lene Christiansen
- Unit of Epidemiology, Biostatistics and BiodemographyDepartment of Public HealthUniversity of Southern DenmarkOdenseDenmark
- Department of Clinical ImmunologyCopenhagen University HospitalRigshospitaletCopenhagen ØDenmark
| | - Kaare Christensen
- Unit of Epidemiology, Biostatistics and BiodemographyDepartment of Public HealthUniversity of Southern DenmarkOdenseDenmark
- Unit of Human GeneticsDepartment of Clinical ResearchUniversity of Southern DenmarkOdenseDenmark
| | - Jacob V. B. Hjelmborg
- Unit of Epidemiology, Biostatistics and BiodemographyDepartment of Public HealthUniversity of Southern DenmarkOdenseDenmark
| | - Qihua Tan
- Unit of Epidemiology, Biostatistics and BiodemographyDepartment of Public HealthUniversity of Southern DenmarkOdenseDenmark
- Unit of Human GeneticsDepartment of Clinical ResearchUniversity of Southern DenmarkOdenseDenmark
| |
Collapse
|
2
|
Fond G, d'Albis MA, Jamain S, Tamouza R, Arango C, Fleischhacker WW, Glenthøj B, Leweke M, Lewis S, McGuire P, Meyer-Lindenberg A, Sommer IE, Winter-van Rossum I, Kapur S, Kahn RS, Rujescu D, Leboyer M. The promise of biological markers for treatment response in first-episode psychosis: a systematic review. Schizophr Bull 2015; 41:559-73. [PMID: 25759473 PMCID: PMC4393702 DOI: 10.1093/schbul/sbv002] [Citation(s) in RCA: 75] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Successful treatment of first-episode psychosis is one of the major factors that impacts long-term prognosis. Currently, there are no satisfactory biological markers (biomarkers) to predict which patients with a first-episode psychosis will respond to which treatment. In addition, a non-negligible rate of patients does not respond to any treatment or may develop side effects that affect adherence to the treatments as well as negatively impact physical health. Thus, there clearly is a pressing need for defining biomarkers that may be helpful to predict response to treatment and sensitivity to side effects in first-episode psychosis. The present systematic review provides (1) trials that assessed biological markers associated with antipsychotic response or side effects in first-episode psychosis and (2) potential biomarkers associated with biological disturbances that may guide the choice of conventional treatments or the prescription of innovative treatments. Trials including first-episode psychoses are few in number. Most of the available data focused on pharmacogenetics markers with so far only preliminary results. To date, these studies yielded-beside markers for metabolism of antipsychotics-no or only a few biomarkers for response or side effects, none of which have been implemented in daily clinical practice. Other biomarkers exploring immunoinflammatory, oxidative, and hormonal disturbances emerged as biomarkers of first-episode psychoses in the last decades, and some of them have been associated with treatment response. In addition to pharmacogenetics, further efforts should focus on the association of emergent biomarkers with conventional treatments or with innovative therapies efficacy, where some preliminary data suggest promising results.
Collapse
Affiliation(s)
| | | | | | - Ryad Tamouza
- Jean Dausset Laboratory & INSERM, UMRS 940, Hôpital Saint Louis, Paris, France
| | - Celso Arango
- Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, CIBERSAM, Madrid, Spain
| | | | - Birte Glenthøj
- Center for Neuropsychiatric Schizophrenia Research & Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, Psychiatric Hospital Center Glostrup, University of Copenhagen, Faculty of Health and Medical Sciences, Denmark
| | - Markus Leweke
- Central Institute of Mental Health, University of Heidelberg/Medical Faculty Mannheim, Mannheim, Germany
| | - Shôn Lewis
- Institute of Brain, Behaviour and Mental Health, University of Manchester, Manchester, UK
| | - Phillip McGuire
- Department of Psychosis Studies, Institute of Psychiatry, King's College London, London, UK
| | - Andreas Meyer-Lindenberg
- Central Institute of Mental Health, University of Heidelberg/Medical Faculty Mannheim, Mannheim, Germany
| | - Iris E Sommer
- Department of Psychiatry, Brain Center Rudolf Magnus, UMC Utrecht, Utrecht, The Netherlands
| | - Inge Winter-van Rossum
- Department of Psychiatry, Brain Center Rudolf Magnus, UMC Utrecht, Utrecht, The Netherlands
| | - Shitij Kapur
- Institute of Psychiatry, King's College London, London, UK
| | - René S Kahn
- Department of Psychiatry, Brain Center Rudolf Magnus, UMC Utrecht, Utrecht, The Netherlands
| | - Dan Rujescu
- Department of Psychiatry, University of Halle, Halle, Germany
| | | |
Collapse
|
3
|
Rubin LH, Carter CS, Bishop JR, Pournajafi-Nazarloo H, Drogos LL, Hill SK, Ruocco AC, Keedy SK, Reilly JL, Keshavan MS, Pearlson GD, Tamminga CA, Gershon ES, Sweeney JA. Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders. Schizophr Bull 2014; 40:1374-84. [PMID: 24619535 PMCID: PMC4193712 DOI: 10.1093/schbul/sbu027] [Citation(s) in RCA: 73] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Oxytocin (OT) and arginine vasopressin (AVP) exert robust influence on social affiliation and specific cognitive processes in healthy individuals. Abnormalities in these neuroendocrine systems have been observed in psychotic disorders, but their relation to impairments in behavioral domains that these endocrines modulate is not well understood. We compared abnormalities of OT and AVP serum concentrations in probands with schizophrenia (n = 57), schizoaffective disorder (n = 34), and psychotic bipolar disorder (n = 75); their first-degree relatives without a history of psychosis (n = 61, 43, 91, respectively); and healthy controls (n = 66) and examined their association with emotion processing and cognition. AVP levels were lower in schizophrenia (P = .002) and bipolar probands (P = .03) and in relatives of schizophrenia probands (P = .002) compared with controls. OT levels did not differ between groups. Familiality estimates were robust for OT (h(2) = 0.79, P = 3.97e-15) and AVP (h(2) = 0.78, P = 3.93e-11). Higher levels of OT were associated with better emotion recognition (β = 0.40, P < .001) and general neuropsychological function (β = 0.26, P = .04) in healthy controls as expected but not in any proband or relative group. In schizophrenia, higher OT levels were related to greater positive symptom severity. The dissociation of OT levels and behavioral function in all proband and relative groups suggests that risk and illness factors associated with psychotic disorders are not related to reduced OT levels but to a disruption in the ability of physiological levels of OT to modulate social cognition and neuropsychological function. Decreased AVP levels may be a marker of biological vulnerability in schizophrenia because alterations were seen in probands and relatives, and familiality was high.
Collapse
Affiliation(s)
- Leah H Rubin
- Department of Psychiatry, University of Illinois at Chicago, Chicago, IL;
| | - C Sue Carter
- Department of Psychiatry, University of North Carolina, Chapel Hill, NC
| | - Jeffrey R Bishop
- Department of Psychiatry, University of Illinois at Chicago, Chicago, IL; Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL
| | | | - Lauren L Drogos
- Department of Psychiatry, University of Illinois at Chicago, Chicago, IL
| | - S Kristian Hill
- Department of Psychology, Rosalind Franklin University of Medicine and Science, North Chicago, IL
| | | | - Sarah K Keedy
- Department of Psychiatry, University of Chicago, Chicago, IL
| | - James L Reilly
- Department of Psychiatry and Behavioral Sciences, Northwestern University, Chicago, IL
| | - Matcheri S Keshavan
- Department of Psychiatry, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
| | - Godfrey D Pearlson
- Department of Psychiatry and Neurobiology, Yale University and Olin Neuropsychiatric Research Center, Hartford, CT
| | - Carol A Tamminga
- Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX
| | | | - John A Sweeney
- Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX
| |
Collapse
|
4
|
Rubin LH, Carter CS, Bishop JR, Pournajafi-Nazarloo H, Harris MSH, Hill SK, Reilly JL, Sweeney JA. Peripheral vasopressin but not oxytocin relates to severity of acute psychosis in women with acutely-ill untreated first-episode psychosis. Schizophr Res 2013; 146:138-43. [PMID: 23465965 PMCID: PMC3622845 DOI: 10.1016/j.schres.2013.01.019] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/19/2012] [Revised: 01/03/2013] [Accepted: 01/07/2013] [Indexed: 01/26/2023]
Abstract
BACKGROUND In women with chronic schizophrenia, higher levels of peripheral oxytocin have been associated with lower levels of positive but not negative symptoms. Sex-specific associations between endogenous levels of oxytocin (OT) and arginine vasopressin (AVP) with clinical symptoms and cognition in untreated early course patients have not been examined. METHOD Clinical ratings and neuropsychological testing were performed in thirty-eight acutely ill, unmedicated first-episode schizophrenia patients (14 women, 24 men). Serum hormone assays were obtained in patients and thirty-eight demographically similar healthy controls. RESULTS Patients demonstrated increased AVP levels compared to controls (p = 0.01). Higher AVP levels were associated with greater positive symptoms (r = 0.58, p = 0.03) and worse verbal learning (r = -0.63, p = 0.02) in female, but not male, patients. OT levels did not statistically differ between patients and controls, and were unrelated to clinical symptoms or cognition in patients. CONCLUSION Results suggest an association of endogenous AVP with increased positive symptom severity and worse cognition in untreated female, but not male, schizophrenia patients. Findings support the role of neuroendocrine alterations in acute psychosis and the importance of examining sex-specific neuroendocrine alterations early in the course of schizophrenia.
Collapse
Affiliation(s)
- Leah H Rubin
- Department of Psychiatry, University of Illinois at Chicago, Chicago, IL 60612, USA.
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Carter JS, Williams HG, Davis JM, Rotter RA, Clancy ME. Effects of DDAVP on movement planning and execution processes in healthy young adults. Peptides 1991; 12:1-5. [PMID: 2052484 DOI: 10.1016/0196-9781(91)90157-k] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
This study investigated the effects of an acute dose of DDAVP on speed and consistency of planning and execution of simple and complex movements in healthy young adults. A simple reaction time task (SRT), a simple movement task (SMT), and a complex movement task (CMT) were performed with and without a 0.6 ml intranasal dose (60 micrograms) of DDAVP. Results indicated DDAVP-treated individuals planned and executed CMT and SRT tasks faster and more consistently than did placebo-treated subjects. There were nonsignificant DDAVP effects on speed and variability of both RT and MT processes involved in the SMT.
Collapse
Affiliation(s)
- J S Carter
- Department of Exercise Science, University of South Carolina, Columbia 29208
| | | | | | | | | |
Collapse
|
6
|
Veldhuis HD, van Wimersma Greidanus TB, Versteeg DH. Microinjection of anti-vasopressin serum into limbic structures of the rat brain: effects on passive avoidance responding and on local catecholamine utilization. Brain Res 1987; 425:167-73. [PMID: 3427417 DOI: 10.1016/0006-8993(87)90495-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Rats which had received bilateral microinjections of 1:50 diluted anti-vasopressin serum into the dorsal or ventral hippocampus, immediately after the learning trial of a one-trial passive avoidance test, showed a reduction in avoidance latency scores during subsequent retention tests 24 and 48 h later. Postlearning microinjection of anti-vasopressin serum into either the dorsolateral septum or the caudate nucleus was without effect on the retention of passive avoidance behavior. Microinjection of anti-vasopressin serum 1 h before the 24-h retention session into either the dorsal hippocampus, the ventral hippocampus or the dorsolateral septum attenuated avoidance responding during both the 24-h and 48-h retention sessions, whereas preretention microinjection of the serum into the caudate nucleus was not effective. Intracerebroventricular administration of the anti-vasopressin serum in amounts similar to those used in the microinjection experiments did not affect retention scores when given either immediately after the learning trial or before the first retention session. One week after the behavioral experiments, a repeated microinjection of anti-vasopressin serum decreased the local alpha-methyl-p-tyrosine methylester (alpha-MPT)-induced disappearance of noradrenaline in the ventral hippocampus and the dorsal hippocampus respectively. Microinjection of the antiserum in the dorsolateral septum enhanced noradrenaline disappearance in this brain region. No effect was found on alpha-MPT-induced dopamine disappearance in the caudate nucleus following local microinjection of anti-vasopressin serum.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- H D Veldhuis
- Rudolf Magnus Institute for Pharmacology, Medical Faculty, University of Utrecht, The Netherlands
| | | | | |
Collapse
|
7
|
|
8
|
Kovács GL, Szabó G, Sarnyai Z, Telegdy G. Neurohypophyseal hormones and behavior. PROGRESS IN BRAIN RESEARCH 1987; 72:109-18. [PMID: 3303126 DOI: 10.1016/s0079-6123(08)60200-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
9
|
|
10
|
Jolles J. Neuropeptides and the treatment of cognitive deficits in aging and dementia. PROGRESS IN BRAIN RESEARCH 1986; 70:429-41. [PMID: 3033743 DOI: 10.1016/s0079-6123(08)64320-4] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
11
|
van Wimersma Greidanus TB, Jolles J, De Wied D. Hypothalamic neuropeptides and memory. Acta Neurochir (Wien) 1985; 75:99-105. [PMID: 3993453 DOI: 10.1007/bf01406329] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Vasopressin and oxytocin exert pronounced effects on behavior by a direct action on the brain. A single injection of vasopressin results in a long-term inhibition of extinction of a conditioned avoidance response suggesting that vasopressin triggers a long-term effect on the maintenance of a learned response, probably by facilitation of memory processes. In addition vasopressin improves passive avoidance behavior, facilitates retention of sexually motivated T-maze choice behavior in male rats, delays extinction of an appetitive discrimination task, affects approach behavior to an imprinting stimulus in ducklings, delays the postcastration decline in copulatory behavior in male rats, prevents or reverses amnesia induced by electroconvulsive shock, CO2 inhalation, pentylenetetrazol or puromycin. The majority of these effects may be explained by stimulatory influences of vasopressin on memory processes. Generally oxytocin exerts effects which are opposite to those of vasopressin and it has been suggested that oxytocin may be an amnesic neuropeptide. Evidence has been obtained that endogenous vasopressin and oxytocin play a physiological role in brain processes related to memory. Various limbic system structures seem to act as the anatomical substrate for the behavioral effects of vasopressin and different neurotransmitter systems seem to be involved. It is postulated that in case vasopressin affects retrieval processes the site of action is located in the amygdala and the dentate gyrus of the hippocampal complex with dopamine and serotonin as the respective neurotransmitter systems involved.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
|
12
|
Van Wimersma Greidanus TB, Veldhuis HD. Vasopressin: site of behavioral action and role in human mental performance. Peptides 1985; 6 Suppl 2:177-80. [PMID: 4080615 DOI: 10.1016/0196-9781(85)90152-4] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Diminishment of endogenous vasopressin in various brain areas (dorsal and ventral hippocampus, dorsal septum) by local application of diluted anti-vasopressin serum results in attenuation of passive avoidance behavior of rats. Both post-learning or pre-retention treatment results in impaired behavior when the anti-vasopressin serum was applied in the dorsal or ventral hippocampus, whereas only pre-retention but not post-learning application of the antiserum in the dorsal septum induced behavioral impairment. Only injection of less diluted antiserum into the lateral ventricle results in attenuation of passive avoidance behavior. These results suggest that endogenous vasopressin present in these brain sites plays a functional role in brain processes related to memory and in particular in processes involved in storage and/or retrieval of information. These findings are discussed and compared with observations of vasopressin treatment on memory functions in man. The observation that some patients with memory disorders do not respond to vasopressin treatment may be due to lesions in the anatomical sites of action of vasopressin.
Collapse
|